Orally administered dipeptidyl peptidase-4 inhibitor (alogliptin) prevents abdominal aortic aneurysm formation through an antioxidant effect in rats

Journal of Vascular Surgery

Volumn 59, Issue 4, 2014, Pages 1098-1108

  Bao, Wulan ^a   Morimoto, Keisuke ^a   Hasegawa, Tomomi ^a   Sasaki, Naoto ^a   Yamashita, Tomoya ^a   Hirata, Kenichi ^a   Okita, Yutaka ^a   Okada, Kenji ^a  

^a KOBE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

8 HYDROXYDEOXYGUANOSINE; ALOGLIPTIN; CALCIUM CHLORIDE; DIPEPTIDYL PEPTIDASE IV INHIBITOR; DNA; ELASTIN; EOSIN; HEMATOXYLIN; HYDROETHIDINE; MATRIX METALLOPROTEINASE; MESSENGER RNA; REACTIVE OXYGEN METABOLITE;

ABDOMINAL AORTA ANEURYSM; ANEURYSM; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIOXIDANT ACTIVITY; AORTA WALL; ARTICLE; CONTROLLED STUDY; DILATATION; DRUG ADMINISTRATION ROUTE; DRUG MEGADOSE; GLUCOSE BLOOD LEVEL; IMMUNOHISTOCHEMISTRY; LOW DRUG DOSE; MALE; NONHUMAN; OXIDATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT;

ADMINISTRATION, ORAL; ANIMALS; ANTIOXIDANTS; AORTA, ABDOMINAL; AORTIC ANEURYSM, ABDOMINAL; BLOOD GLUCOSE; CALCIUM CHLORIDE; DEOXYGUANOSINE; DILATATION, PATHOLOGIC; DIPEPTIDYL PEPTIDASE 4; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; DISEASE MODELS, ANIMAL; DNA DAMAGE; DOSE-RESPONSE RELATIONSHIP, DRUG; GENE EXPRESSION REGULATION, ENZYMOLOGIC; MALE; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; OXIDATIVE STRESS; PANCREATIC ELASTASE; PIPERIDINES; RATS; RATS, SPRAGUE-DAWLEY; REACTIVE OXYGEN SPECIES; RNA, MESSENGER; TIME FACTORS; URACIL;

EID: 84897084605     PISSN: 07415214     EISSN: 10976809     Source Type: Journal    
DOI: 10.1016/j.jvs.2013.04.048     Document Type: Article

References (39)

1. K.A. Vardulaki, T.C. Prevost, N.M. Walker, N.E. Day, A.B. Wilmink, and C.R. Quick et al. Incidence among men of asymptomatic abdominal aortic aneurysms: estimates from 500 screen detected cases J Med Screen 6 1999 50 54
2. T.B. Wilmink, C.R. Quick, C.S. Hubbard, and N.E. Day The influence of screening on the incidence of ruptured abdominal aortic aneurysms J Vasc Surg 30 1999 203 208
3. S.H. Forsdahl, K. Singh, S. Solberg, and B.K. Jacobsen Risk factors for abdominal aortic aneurysms: a 7-year prospective study: the Tromso Study, 1994-2001 Circulation 119 2009 2202 2208
4. K.A. Gelderman, M. Hultqvist, L.M. Olsson, K. Bauer, A. Pizzolla, and P. Olofsson et al. Rheumatoid arthritis: the role of reactive oxygen species in disease development and therapeutic strategies Antioxid Redox Signal 9 2007 1541 1567
5. T. Lu, Q. Chai, L. Yu, L.V. d'Uscio, Z.S. Katusic, and T. He et al. Reactive oxygen species signaling facilitates FOXO-3a/FBXO-dependent vascular BK channel beta1 subunit degradation in diabetic mice Diabetes 61 2012 1860 1868
6. R.L. Yang, Y.H. Shi, G. Hao, W. Li, and G.W. Le Increasing oxidative stress with progressive hyperlipidemia in human: relation between malondialdehyde and atherogenic index J Clin Biochem Nutr 43 2008 154 158
7. K.K. Griendling, D. Sorescu, and M. Ushio-Fukai NAD(P)H oxidase: role in cardiovascular biology and disease Circ Res 86 2000 494 501
8. M. Haidari, M. Ali, L. Gangehei, M. Chen, W. Zhang, and M.I. Cybulsky Increased oxidative stress in atherosclerosis-predisposed regions of the mouse aorta Life Sci 87 2010 100 110
9. T. Kishi, Y. Hirooka, Y. Kimura, K. Ito, H. Shimokawa, and A. Takeshita Increased reactive oxygen species in rostral ventrolateral medulla contribute to neural mechanisms of hypertension in stroke-prone spontaneously hypertensive rats Circulation 109 2004 2357 2362
10. M.J. Somers, K. Mavromatis, Z.S. Galis, and D.G. Harrison Vascular superoxide production and vasomotor function in hypertension induced by deoxycorticosterone acetate-salt Circulation 101 2000 1722 1728
11. M.L. McCormick, D. Gavrila, and N.L. Weintraub Role of oxidative stress in the pathogenesis of abdominal aortic aneurysms Arterioscler Thromb Vasc Biol 27 2007 461 469
12. T. Miyake, and R. Morishita Pharmacological treatment of abdominal aortic aneurysm Cardiovasc Res 83 2009 436 443
13. W. Xiong, J. Mactaggart, R. Knispel, J. Worth, Z. Zhu, and Y. Li et al. Inhibition of reactive oxygen species attenuates aneurysm formation in a murine model Atherosclerosis 202 2009 128 134
14. K. Morimoto, T. Hasegawa, A. Tanaka, B. Wulan, J. Yu, and N. Morimoto et al. Free-radical scavenger edaravone inhibits both formation and development of abdominal aortic aneurysm in rats J Vasc Surg 55 2012 1749 1758
15. K. Chinda, S. Palee, S. Surinkaew, M. Phornphutkul, S. Chattipakorn, and N. Chattipakorn Cardioprotective effect of dipeptidyl peptidase-4 inhibitor during ischemia-reperfusion injury Int J Cardiol 2012 January 26 [Epublication ahead of print] http://dx.doi.org/10.1016/j.ijcard.2012.01.011
16. A. Tanaka, T. Hasegawa, Z. Chen, Y. Okita, and K. Okada A novel rat model of abdominal aortic aneurysm using a combination of intraluminal elastase infusion and extraluminal calcium chloride exposure J Vasc Surg 50 2009 1423 1432
17. I. De Meester, S. Korom, J. Van Damme, and S. Scharpé CD26, let it cut or cut it down Immunol Today 20 1999 367 375
18. A.M. El-Asrar, S. Struyf, S.A. Al-Kharashi, L. Missotten, D.J. Van, and K. Geboes Expression of T lymphocyte chemoattractants and activation markers in vernal keratoconjunctivitis Br J Ophthalmol 86 2002 1175 1180
19. D. Reinhold, U. Bank, F. Buhling, T. Kahne, D. Kunt, and J. Faust et al. Inhibitors of dipeptidyl peptidase IV (DP IV, CD26) specifically suppress proliferation and modulate cytokine production of strongly CD26 expressing U937 cells Immunobiology 192 1994 121 136
20. D. Reinhold, S. Wrenger, U. Bank, F. Buhling, T. Hoffmann, and K. Neubert et al. CD26 mediates the action of HIV-1 Tat protein on DNA synthesis and cytokine production in U937 cells Immunobiology 195 1996 119 128
21. D. Reinhold, R.W. Vetter, K. Mnich, F. Buhling, U. Lendeckel, and I. Born et al. Dipeptidyl peptidase IV (DP IV, CD26) is involved in regulation of DNA synthesis in human keratinocytes FEBS Lett 428 1998 100 104
22. N.N. Ta, Y. Li, C.A. Schuyler, M.F. Lopes-Virella, and Y. Huang DPP-4 (CD26) inhibitor alogliptin inhibits TLR4-mediated ERK activation and ERK-dependent MMP-1 expression by U937 histiocytes Atherosclerosis 213 2010 429 435
23. Z. Shah, T. Kampfrath, J.A. Deiuliis, J. Zhong, C. Pineda, and Z. Ying et al. Long-term dipeptidyl-peptidase 4 inhibition reduces atherosclerosis and inflammation via effects on monocyte recruitment and chemotaxis Circulation 124 2011 2338 2349
24. T. Asakawa, Y. Moritoh, O. Kataoka, N. Suzuki, K. Takeuchi, and H. Odaka A novel dipeptidyl peptidase-4 inhibitor, alogliptin (SYR-322), is effective in diabetic rats with sulfonylurea-induced secondary failure Life Sci 85 2009 122 126
25. F.J. Miller Jr., D.D. Gutterman, C.D. Rios, D.D. Heistad, and B.L. Davidson Superoxide production in vascular smooth muscle contributes to oxidative stress and impaired relaxation in atherosclerosis Circ Res 82 1998 1298 1305
26. K.K. Griendling, and G.A. FitzGerald Oxidative stress and cardiovascular injury: part I: basic mechanisms and in vivo monitoring of ROS Circulation 108 2003 1912 1916
27. M. Thomas, D. Gavrila, M.L. McCormick, F.J. Miller Jr., A. Daugherty, and L.A. Cassis et al. Deletion of p47phox attenuates angiotensin II-induced abdominal aortic aneurysm formation in apolipoprotein E-deficient mice Circulation 114 2006 404 413
28. P.F. Li, R. Dietz, and H.R. von Reactive oxygen species induce apoptosis of vascular smooth muscle cell FEBS Lett 404 1997 249 252
29. S. Rajagopalan, X.P. Meng, S. Ramasamy, D.G. Harrison, and Z.S. Galis Reactive oxygen species produced by macrophage-derived foam cells regulate the activity of vascular matrix metalloproteinases in vitro. Implications for atherosclerotic plaque stability J Clin Invest 98 1996 2572 2579
30. V.R. Winrow, P.G. Winyard, C.J. Morris, and D.R. Blake Free radicals in inflammation: second messengers and mediators of tissue destruction Br Med Bull 49 1993 506 522
31. D. Gavrila, W.G. Li, M.L. McCormick, M. Thomas, A. Daugherty, and L.A. Cassis et al. Vitamin E inhibits abdominal aortic aneurysm formation in angiotensin II-infused apolipoprotein E-deficient mice Arterioscler Thromb Vasc Biol 25 2005 1671 1677
32. G.M. Longo, W. Xiong, T.C. Greiner, Y. Zhao, N. Fiotti, and B.T. Baxter Matrix metalloproteinases 2 and 9 work in concert to produce aortic aneurysms J Clin Invest 110 2002 625 632
33. R. Pyo, J.K. Lee, J.M. Shipley, J.A. Curci, D. Mao, and S.J. Ziporin et al. Targeted gene disruption of matrix metalloproteinase-9 (gelatinase B) suppresses development of experimental abdominal aortic aneurysms J Clin Invest 105 2000 1641 1649
34. P. Covington, R. Christopher, M. Davenport, P. Fleck, Q.A. Mekki, and E.R. Wann et al. Pharmacokinetic, pharmacodynamic, and tolerability profiles of the dipeptidyl peptidase-4 inhibitor alogliptin: a randomized, double-blind, placebo-controlled, multiple-dose study in adult patients with type 2 diabetes Clin Ther 30 2008 499 512
35. J.P. Habashi, J.J. Doyle, T.M. Holm, H. Aziz, F. Schoenhoff, and D. Bedja et al. Angiotensin II type 2 receptor signaling attenuates aortic aneurysm in mice through ERK antagonism Science 332 2011 361 365
36. K. Kajimoto, K. Miyauchi, T. Kasai, K. Shimada, Y. Kojima, and A. Shimada et al. Short-term 20-mg atorvastatin therapy reduces key inflammatory factors including c-Jun N-terminal kinase and dendritic cells and matrix metalloproteinase expression in human abdominal aortic aneurysmal wall Atherosclerosis 206 2009 505 511
37. L.D. Lazar, M.J. Pletcher, P.G. Coxson, K. Bibbins-Domingo, and L. Goldman Cost-effectiveness of statin therapy for primary prevention in a low-cost statin era Circulation 124 2011 146 153
38. S. Kheterpal, O. Khodaparast, A. Shanks, M. O'Reilly, and K.K. Tremper Chronic angiotensin-converting enzyme inhibitor or angiotensin receptor blocker therapy combined with diuretic therapy is associated with increased episodes of hypotension in noncardiac surgery J Cardiothorac Vasc Anesth 22 2008 180 186
39. I.S. Anand, K. Bishu, T.S. Rector, A. Ishani, M.A. Kuskowski, and J.N. Cohn Proteinuria, chronic kidney disease, and the effect of an angiotensin receptor blocker in addition to an angiotensin-converting enzyme inhibitor in patients with moderate to severe heart failure Circulation 120 2009 157 184